Screener
BioMarin Pharmaceuticals BMRN VIMIZIM — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| VOXZOGO | $252,528 | $221,391 | $472,408 | $435,145 |
| Metabolic Conditions (formerly Enzyme Therapies): | ||||
| VIMIZIM | 194,371 | 215,424 | 404,575 | 403,770 |
| NAGLAZYME | 135,255 | 128,867 | 265,329 | 243,157 |
| PALYNZIQ | 135,167 | 105,938 | 224,725 | 199,207 |
| GALAFOLD(1) | 105,748 | — | 105,748 | — |
| BRINEURA | 51,370 | 48,692 | 98,474 | 89,054 |
| ALDURAZYME | 43,539 | 56,437 | 80,281 | 105,414 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's VIMIZIM — total revenues?
- BioMarin Pharmaceuticals (BMRN) reported VIMIZIM — total revenues of $194.37M in Q2 2026.
- How has BioMarin Pharmaceuticals's VIMIZIM — total revenues changed year-over-year?
- BioMarin Pharmaceuticals's VIMIZIM — total revenues decreased by 9.8% year-over-year, from $215.42M to $194.37M.
- What is the long-term trend for BioMarin Pharmaceuticals's VIMIZIM — total revenues?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's VIMIZIM — total revenues has grown at a 6.2% compound annual growth rate (CAGR), from $623.15M to $792.05M.
- What does VIMIZIM — total revenues mean?
- This metric represents the total gross revenue generated from the sale of a specific therapeutic product within the company's rare disease portfolio. It captures the aggregate financial inflow from global commercialization efforts, including product sales and related licensing or distribution arrangements. This figure serves as a primary indicator of the product's market penetration and commercial success within its specific patient population.
Ask your AI about BioMarin Pharmaceuticals's vimizim — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude